
-
Cellectar Biosciences NasdaqCM:CLRB Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Location: 100 Campus Drive, Florham Park, NJ, 07932, United States | Website: https://www.cellectar.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-745K
Cash
13.91M
Avg Qtr Burn
-10.9M
Short % of Float
5.28%
Insider Ownership
1.71%
Institutional Own.
12.42%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Iopofosine (CLR 131) Details Cancer, B-cell lymphoma, Lymphoma | Phase 2 Update | |
Iopofosine (CLR 131) Details Multiple myeloma, Cancer, High Refractory Multiple Myeloma | Phase 2 Update | |
Iopofosine (CLR 131) Details Waldenstrom macroglobulinemia | Phase 2 Update | |
CLR 121125 Details Triple-negative breast cancer | Phase 1/2 Initiation | |
Iopofosine (CLR 131) Details Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma
| Phase 1b Data readout | |
Iopofosine (CLR 131) + EBRT Details Head and neck cancer, Head and neck squamous cell carcinoma | Phase 1 Update |